AU2021240769B2 - Antibodies binding Siglec15 and uses thereof - Google Patents

Antibodies binding Siglec15 and uses thereof Download PDF

Info

Publication number
AU2021240769B2
AU2021240769B2 AU2021240769A AU2021240769A AU2021240769B2 AU 2021240769 B2 AU2021240769 B2 AU 2021240769B2 AU 2021240769 A AU2021240769 A AU 2021240769A AU 2021240769 A AU2021240769 A AU 2021240769A AU 2021240769 B2 AU2021240769 B2 AU 2021240769B2
Authority
AU
Australia
Prior art keywords
antibody
siglec15
chain variable
variable region
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021240769A
Other languages
English (en)
Other versions
AU2021240769A1 (en
Inventor
Mingjiu Chen
Shukai Xia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosion Inc
Original Assignee
Biosion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosion Inc filed Critical Biosion Inc
Publication of AU2021240769A1 publication Critical patent/AU2021240769A1/en
Application granted granted Critical
Publication of AU2021240769B2 publication Critical patent/AU2021240769B2/en
Priority to AU2023203397A priority Critical patent/AU2023203397A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2021240769A 2020-03-27 2021-03-26 Antibodies binding Siglec15 and uses thereof Active AU2021240769B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023203397A AU2023203397A1 (en) 2020-03-27 2023-05-31 Antibodies binding Siglec15 and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000566P 2020-03-27 2020-03-27
US63/000,566 2020-03-27
PCT/CN2021/083194 WO2021190622A1 (en) 2020-03-27 2021-03-26 Antibodies binding siglec15 and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023203397A Division AU2023203397A1 (en) 2020-03-27 2023-05-31 Antibodies binding Siglec15 and uses thereof

Publications (2)

Publication Number Publication Date
AU2021240769A1 AU2021240769A1 (en) 2022-10-20
AU2021240769B2 true AU2021240769B2 (en) 2023-04-06

Family

ID=77891322

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021240769A Active AU2021240769B2 (en) 2020-03-27 2021-03-26 Antibodies binding Siglec15 and uses thereof
AU2023203397A Pending AU2023203397A1 (en) 2020-03-27 2023-05-31 Antibodies binding Siglec15 and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023203397A Pending AU2023203397A1 (en) 2020-03-27 2023-05-31 Antibodies binding Siglec15 and uses thereof

Country Status (12)

Country Link
US (2) US11739147B2 (https=)
EP (1) EP4126938A4 (https=)
JP (2) JP7364315B2 (https=)
KR (1) KR102651263B1 (https=)
CN (1) CN115348970B (https=)
AU (2) AU2021240769B2 (https=)
BR (1) BR112022019129A2 (https=)
IL (1) IL296736B2 (https=)
MX (1) MX2022011951A (https=)
PH (1) PH12022552520A1 (https=)
SA (1) SA522440646B1 (https=)
WO (1) WO2021190622A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021240769B2 (en) * 2020-03-27 2023-04-06 Biosion Inc. Antibodies binding Siglec15 and uses thereof
US20260070974A1 (en) * 2021-11-25 2026-03-12 Nona Biosciences (Suzhou) Co., Ltd. Anti-siglec-15 antibody and use thereof
CN114134183B (zh) * 2021-12-24 2022-12-06 广东南模生物科技有限公司 一种siglec15基因人源化动物模型的构建方法及应用
CN114807052A (zh) * 2022-06-07 2022-07-29 江苏亲科生物研究中心有限公司 Siglec15单克隆抗体及其制备方法和用途
CA3259231A1 (en) * 2022-06-13 2023-12-21 Shanghai Institute Of Biological Products Co., Ltd. ANTI-SIGLEC15 ANTIBODIES AND THEIR USES
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2025247334A1 (en) * 2024-05-30 2025-12-04 Biosion Inc. Recombinant fusion protein targeting siglec15 and gm-csfr

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102803293A (zh) * 2009-10-06 2012-11-28 阿莱斯亚生物疗法股份有限公司 治疗骨丢失相关疾病的siglec 15抗体
CN104321430A (zh) * 2012-03-30 2015-01-28 第一三共株式会社 新颖的抗-siglec-15抗体
WO2018057735A1 (en) * 2016-09-21 2018-03-29 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
CN108430498A (zh) * 2015-11-10 2018-08-21 耶鲁大学 用于治疗自身免疫疾病和癌症的组合物及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4604184B2 (ja) * 2005-07-12 2010-12-22 独立行政法人産業技術総合研究所 新規糖鎖認識蛋白質及びその遺伝子
JP2013543382A (ja) * 2010-10-05 2013-12-05 第一三共株式会社 破骨細胞関連蛋白質Ｓｉｇｌｅｃ−１５を標的とした抗体
ES2908046T3 (es) 2011-09-09 2022-04-27 Medimmune Ltd Anticuerpos anti-siglec-15 y usos de los mismos.
US9493562B2 (en) * 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
WO2015192214A1 (en) * 2014-06-18 2015-12-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies for use in treatment of osteogenesis imperfecta
CN108250296B (zh) * 2018-01-17 2020-07-07 长春金赛药业有限责任公司 全人源抗人pd-l1单克隆抗体及其应用
JP7156653B2 (ja) * 2018-08-30 2022-10-19 イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ 固形腫瘍を治療するためのキメラ抗原受容体細胞
AU2021240769B2 (en) * 2020-03-27 2023-04-06 Biosion Inc. Antibodies binding Siglec15 and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102803293A (zh) * 2009-10-06 2012-11-28 阿莱斯亚生物疗法股份有限公司 治疗骨丢失相关疾病的siglec 15抗体
CN104321430A (zh) * 2012-03-30 2015-01-28 第一三共株式会社 新颖的抗-siglec-15抗体
CN108430498A (zh) * 2015-11-10 2018-08-21 耶鲁大学 用于治疗自身免疫疾病和癌症的组合物及方法
WO2018057735A1 (en) * 2016-09-21 2018-03-29 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof

Also Published As

Publication number Publication date
KR102651263B1 (ko) 2024-03-25
IL296736B1 (en) 2024-12-01
CA3173201A1 (en) 2021-09-30
NZ792658A (en) 2024-07-05
US11739147B2 (en) 2023-08-29
IL296736A (en) 2022-11-01
BR112022019129A2 (pt) 2022-12-06
US20240002508A1 (en) 2024-01-04
CN115348970B (zh) 2023-11-14
WO2021190622A1 (en) 2021-09-30
AU2023203397A1 (en) 2023-06-29
US20230106715A1 (en) 2023-04-06
JP7364315B2 (ja) 2023-10-18
EP4126938A1 (en) 2023-02-08
MX2022011951A (es) 2023-03-06
CN115348970A (zh) 2022-11-15
EP4126938A4 (en) 2024-04-10
SA522440646B1 (ar) 2024-08-29
PH12022552520A1 (en) 2023-01-04
JP2023518153A (ja) 2023-04-28
IL296736B2 (en) 2025-04-01
KR20220158696A (ko) 2022-12-01
AU2021240769A1 (en) 2022-10-20
JP7827951B2 (ja) 2026-03-11
JP2024016024A (ja) 2024-02-06

Similar Documents

Publication Publication Date Title
US12479912B2 (en) Monoclonal antibodies which bind thymic stromal lymphopoietin (TSLP), encoding polynucleotides thereof and methods of use thereof to treat diseases
US20230055711A1 (en) Antibodies binding bcma and uses thereof
AU2021240769B2 (en) Antibodies binding Siglec15 and uses thereof
US20230105029A1 (en) Antibodies binding il4r and uses thereof
US12503517B2 (en) Antibodies binding CD40 and uses thereof
US20250250355A1 (en) Antibodies targeting sirp-alpha and uses thereof
US20200332017A1 (en) Antibodies or antigen-binding portions binding cd40 and uses thereof
US12559565B2 (en) Antibodies binding CTLA4 and uses thereof
AU2021330087B2 (en) PD-1 binding antibodies and uses thereof
WO2021136323A1 (en) Antibodies binding bcma and uses thereof
CA3173201C (en) Antibodies binding siglec15 and uses thereof
US20230167182A1 (en) Antibodies binding il6r and uses thereof
US20230357438A1 (en) Antibodies binding c5 and uses thereof
US20230034768A1 (en) Antibodies binding rankl and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)